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Abstract
Background: Fetal hemoglobin level is a heritable complex trait that strongly correlates swith the clinical severity of sickle
cell disease. Only few genetic loci have been identified as robustly associated with fetal hemoglobin in patients with sickle
cell disease, primarily adults. The sole approved pharmacologic therapy for this disease is hydroxyurea, with effects largely
attributable to induction of fetal hemoglobin.
Methodology/Principal Findings: In a multi-site observational analysis of children with sickle cell disease, candidate single
nucleotide polymorphisms associated with baseline fetal hemoglobin levels in adult sickle cell disease were examined in
children at baseline and induced by hydroxyurea therapy. For baseline levels, single marker analysis demonstrated
significant association with BCL11A and the beta and epsilon globin loci (HBB and HBE, respectively), with an additive
attributable variance from these loci of 23%. Among a subset of children on hydroxyurea, baseline fetal hemoglobin levels
explained 33% of the variance in induced levels. The variant in HBE accounted for an additional 13% of the variance in
induced levels, while variants in the HBB and BCL11A loci did not contribute beyond baseline levels.
Conclusions/Significance: These findings clarify the overlap between baseline and hydroxyurea-induced fetal hemoglobin
levels in pediatric disease. Studies assessing influences of specific sequence variants in these and other genetic loci in larger
populations and in unusual hydroxyurea responders are needed to further understand the maintenance and therapeutic
induction of fetal hemoglobin in pediatric sickle cell disease.
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Introduction
In sickle cell disease, higher fetal hemoglobin (HbF) levels
diminish de-oxygenated sickle globin polymerization in vitro [1]
and reduce the incidence of disease morbidities in vivo [2,3]. HbF
is a heritable complex trait [4,5]. Only three genetic loci have been
validated as strongly associated with higher HbF in sickle cell
disease: the 59 beta globin locus (HBB) [5,6,7,8,9], although not
the sickle mutation; the BCL11A repressor of HbF [5,6,7,8,10,11];
and the HS1L-MYB intergenic region [5,6,8,12]. Other candidate
regions have not been confirmed [10,13,14].
Hydroxyurea is the only approved pharmacologic therapy for
sickle cell disease. Its clinical and laboratory effect is understood to
result largely from enhanced HbF expression [3,15,16], although
induction occurs to a highly variable extent [3,4,16,17,18].
Children generally have higher baseline HbF levels than adults
[13,18] and a stable [15] and overall more robust HbF response to
hydroxyurea [13,18,19]. Hydroxyurea-induced HbF is also
a heritable trait [4] that generally correlates with baseline levels
[18,19,20]. To date, only limited reports have examined relation-
ships between hydroxyurea-induced HbF and specific genetic
polymorphisms in adults with sickle cell disease [13,21] and did
not explore the recently identified major loci of interest. Genetic
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determinants for this clinically relevant marker of drug response
have not been confirmed in children [17,19]. Such insight would
be useful for elucidating mechanisms of hydroxyurea induction
and for predicting individual response.
Our multi-site observational study examined associations
between baseline and hydroxyurea-induced HbF in children with
sickle cell disease and candidate single nucleotide polymorphisms
(SNP) in several genes associated with adult sickle cell HbF levels.
Our results indicate: 1) A 33% contribution of baseline to induced
levels; 2) Confirmation of single marker associations between the
HBB and epsilon globin (HBE) and BCL11A loci and baseline HbF
in children; 2) Association between HBE and hydroxyurea-
induced HbF; 3) Additive effects of these SNPs on baseline and
induced HbF in children.
Materials
Ethics
Studies were performed under the policies of and with specific
approval from the Institutional Review Board (IRB) at Columbia
University and the corresponding body at each of the other
participating institutions: Yale University IRB, Albert Einstein
College of Medicine IRB, Weill Cornell University Medical
School IRB, University of Rochester Research Subjects Review
Board, Children’s Mercy Hospitals and Clinics IRB, Children’s
Hospital & Research Center Oakland IRB. Written informed
consent from parents of participating children and informed assent
from children were obtained according to each institution’s IRB
policies.
Participants
Observational analysis of children attending sickle cell clinic was
performed at five sites (see author affiliations), including pro-
spective observation during 2010. The Oakland site provided
archived data and samples. Clinical inclusion and exclusion
criteria conformed to those previously described [18,22]. Inclusion
criteria are: HbSS or HbS-B0 thalassemia, ages 5–21 years.
Exclusions criteria are: pregnancy, current or recent painful crisis,
fever or other acute illness within three weeks prior to evaluation,
transfusion within the prior 100 days or active transfusion therapy,
abnormal elevated serum creatinine or liver transaminases. We
excluded siblings to ensure genetic independence. Laboratory data
at steady state represented the most recent values obtained during
routine care or an average of three values from well visits over the
preceding 6–12 months, if available. Percent HbF (%HbF) was
determined by routine HPLC and was used as a quantitative trait
at steady state for baseline and for drug-induced levels.
Duration of hydroxyurea treatment was for at least six months
and was initiated for comparable clinical indications across sites
(nearly all for repetitive painful crises and/or acute chest episodes).
Stable hydroxyurea dosing was three months at or near maximal
dose by ANC criteria, excluding data from subjects on less than
20 mg/kg/day, even if for dose-limiting toxicity. Across the six
sites, drug dose averages ranged from 23.8–29 mg/kg/day and
did not statistically differ between sites (F = 1.554, p = 0.210).
Adherence to hydroxyurea was defined as parent report of at least
80% of prescribed doses. Laboratory data at steady state
represented recent values during routine care or averaged three
values from well visits over the preceding 6–12 months, if
available. Percentage of HbF (HbF%) was used as a quantitative
trait. Baseline HbF had not been recorded prior to treatment for
nine of the 47 subjects on hydroxyurea, thus is not available.
Hydroxyurea-associated increased mean red cell volume and
decreased white blood cell count were used to confirm data
quality. For children on hydroxyurea therapy, where available,
clinical response to hydroxyurea was assessed by retrospective
chart review of the number of sickle-related hospitalizations over
the two-year periods preceding and while on hydroxyurea
treatment.
Description of Procedures
Twenty SNPs previously reported as associated with HbF% in
sickle cell disease [6,7,8,9,11,14,17,19] were genotyped (Table 1):
nine in the BCL11A locus; two in HBS1L-MYB intergenic region
on chromosome 6q23; three in the globin locus on chromosome
11: two 59 sites in HBB (including the previously identified XmnI
site [23] and one in HBE [19]; one in OR51 that is upstream of
HBB [14]; one in the glucagon-like peptide-2 receptor, GLP2R,
found by genome-wide analysis [10]; two SNPs from the
hydroxyurea-induced SAR1A locus [21]; one SNP each in ARG1
and ARG2 [19] (SNP sequences available by request).
SNP marker genotyping of minor allele frequencies ranging
from 0.07 to 0.45 was performed using Sequenom MassArray
iPLEX platform with matrix-assisted laser desorption/ionization
time of flight mass spectrometry (Sequenom, San Diego, CA).
PCR assays and mass extension reactions were designed using
mass array assay design software (Sequenom). PCR assays used
Applied Biosystems Geneamp PCR thermocyclers (Foster City,
CA) and analyzed by mass array compact mass spectrometer
(Bruker Daltonik, Billerica, MA) and Spectro TYPER software
(Sequenom). (SNP sequences, PCR and analytic conditions are
available upon request.) Genotyping was performed in duplicate
with separate assays, with genotype frequency distribution at each
SNP tested for deviations from Hardy-Weinberg equilibrium.
Accurate genotyping of SAR1A SNP rs4282891 required sequenc-
ing. The sickle genotype, rs334, was assayed to confirm the
diagnosis for each sample.
Statistical Methods
Relationships between each of the three quantitative HbF
values were assessed by Pearson correlation analysis. Genetic
associations were assessed for candidate SNPs with %HbF at
baseline, on hydroxyurea treatment (‘‘maximum HbF’’), and the
hydroxyurea-induced increment over baseline (‘‘delta HbF’’)
(Table 1). For each HbF value, quantitative associations with
a dose effect model of the minor allele were tested using a linear
regression analysis, adjusted for sex and age. Baseline HbF levels
were log10 transformed to fit a normal distribution; maximum and
delta HbF were normally distributed. Significance is reported for
nominal p-values of 0.05 or less, and with Bonferroni adjustment
of p-values for multiple testing (adjusted p-value of 361023 for the
19 SNPs tested – see below). Given the fixed sample size, power
was estimated based on the smallest detectable differences in the
average levels of baseline and hydroxyurea-induced fetal hemo-
globin HbF. Power was computed using QUANTO software
(http://hydra.usc.edu/gxe/) assuming an additive allele effects
model, an alpha threshold of 0.05, a range of different values for
effect sizes (b) and SNP allele frequency (Figure S2) [24].
Limited number of subjects of each genotype precluded analysis
of potential dose effect of homozygotes. Trend analysis was
performed by analysis of variance tested for individual and
additive effects for each allele. Percentage of variance attributable
to SNPs in BCL11A, HBB and HBE was estimated using linear
regression analysis comparing models consisting of age, sex,
individual SNPs and multiple SNPs with a reduced model
consisting of sex and age (SPSS Inc., Chicago, IL). To evaluate
whether BCL11A haplotypes was in closer linkage disequilibrium
with causal variants than single SNPs, haplotype association
Sequence Variants with Fetal Hb in Sickle Disease
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analysis was performed with PLINK software [25] using a haplo-




117 children from the six sites met study criteria (Data from
each site are shown in Table S1). The mean age and standard
deviation was 12.5 (SD=4.9), with 52% male. Six subjects (5.1%)
had HbS-B0 thalassemia (Table S1A). A subset of children (N= 47)
was on hydroxyurea, 38 of whom had recorded baseline and
maximum HbF values. Hydroxyurea dosing ranged from 20–
30.7 mg/kg/day, averaging 25.3 (SD=3.0) mg/kg/day. During
the two years prior to hydroxyurea therapy, children (N= 22 with
available data) had 0–13 hospital admissions (mean= 3.7,
SD=2.8); only one child had no hospitalizations. During a two
year period while on hydroxyurea therapy, these same children
had 0–6 hospitalizations (mean=1.4,SD=1.5). While on hy-
droxyurea, nearly all had fewer hospitalizations over a two year
period (p = 0.001), and 32% had none.
Mean HbF% values were: baseline HbF 8.0 (SD=4.9,
N= 108), maximum HbF 18.2 (SD=7.1, N=47), and delta
HbF 11.6 (SD=6.3, N= 38). Among those subjects with complete
data for baseline and hydroxyurea-induced HbF (N= 38),
distributions of baseline and induced HbF were comparable to
those previously reported for children on hydroxyurea (Figure 1,
Figure S1) [18] thereby validating our observational data. No
significant effect of gender was detected for any of the three
quantitative traits; age appeared to have some influence on
baseline HbF. Mean baseline HbF at each site ranged from 6.8
(SD=5.0) to 9.8 (SD=5.6), with no significant difference in mean
values (F = 0.808, p= 0.523), excluding the average value of 12.9%
from Rochester (N= 8). At the three sites with at least four subjects
on hydroxyurea (Columbia, Yale and Oakland), no differences
were found in induced maximum or delta HbF (F= 0.668,
p = 0.418 and F= 0.404, p= 0.530, respectively).
Pearson correlation for the 38 children with complete baseline
and hydroxyurea-induced HbF demonstrated high levels of
relatedness for: baseline and induced maximum HbF levels
(r2 = 0.59, p,0.001), similar to previously reported [18]; maxi-
mum and delta HbF (r2 = 0.86, p,0.001); but not between
baseline and delta HbF (r2 = 0.08, p = 0.632). Those in the lowest
quartile for baseline levels were highly likely to remain in the
lowest quartile (Q1) for induced HbF (r2 = 0.565, p,0.001)
(Figure 1). Only two children (5.3%) were induced from the lowest
to highest quartiles (Q3+Q4), and did not appear to differ by age,
sex, sickle type, hydroxyurea dose, genotype, or other discernible
variable, although the small number precluded statistical analysis.
By linear regression analysis adjusted for age and sex, overall
percentage of variance in hydroxyurea-induced HbF attributable
to baseline levels was 33%.
Genetic
Call rates uniformly exceeded 97% for each SNP. One SAR1A
gene SNP, rs428289, [21] was monomorphic in subjects treated
with hydroxyurea, precluding analysis of variants. Genotyping of
the other 19 SNPs revealed minor allele frequencies that were
comparable across the six sites (Table S1B) and to allele
frequencies among sickle cell populations in the U.S and elsewhere







Chr Gene SNP A1 b SE p b SE p b SE p Reference
2 BCL11A rs7581162 T 0.08 0.70 0.908 0.40 1.55 0.796 21.43 1.72 0.412 HapMap
2 BCL11A rs10189857 G 0.10 0.77 0.898 0.27 1.96 0.891 3.57 2.12 0.101 6
2 BCL11A rs1427407 T 2.55 0.69 *461024 2.14 1.64 0.200 0.19 1.64 0.909 19
2 BCL11A rs7599488 T 20.20 0.78 0.803 0.87 1.96 0.659 4.67 2.13 0.035 6
2 BCL11A rs766432 C 2.88 0.68 *561025 3.38 1.59 0.039 1.20 1.60 0.459 10,11,19
2 BCL11A rs11886868 C 2.58 0.64 *161024 3.37 1.38 0.019 1.25 1.42 0.386 7,19
2 BCL11A rs4671393 A 2.88 0.68 *561025 3.38 1.59 0.039 1.20 1.60 0.459 7,19
2 BCL11A rs7557939 G 2.51 0.64 *261024 3.09 1.39 0.031 1.10 1.42 0.446 7,19
2 BCL11A rs10184550 G 2.24 0.66 0.001 2.44 1.36 0.080 20.56 1.45 0.701 11
6 ARG1 rs17599586 T 20.64 1.07 0.549 24.71 2.56 0.073 24.43 2.42 0.076 19
6 HBS1L-MYB rs28384513 C 0.24 0.90 0.792 22.60 1.86 0.170 21.65 1.83 0.373 7
6 HBS1L-MYB rs4895441 G 20.24 1.23 0.846 24.91 3.06 0.116 21.71 3.20 0.595 7
10 SAR1A rs2310991 A 0.05 0.62 0.942 20.60 1.61 0.711 0.03 1.62 0.984 21
11 HBB rs10128556 T 2.63 1.34 0.057 5.25 2.86 0.074 2.53 2.62 0.342 6
11 HBB rs7482144 A 3.88 0.99 *261024 7.61 3.97 0.062 2.69 3.67 0.468 7
11 HBE rs7130110 C 2.86 0.68 *661025 7.82 2.07 *561024 6.04 1.97 0.004 19
11 OR51B6 rs5024042 A 1.70 0.78 0.031 3.04 1.93 0.122 1.68 1.85 0.371 13
14 ARG2 rs2295644 A 1.13 0.76 0.142 20.04 1.79 0.983 20.01 1.91 0.995 19
17 GLP2R rs12103880 A 0.68 0.69 0.324 23.66 1.30 0.008 22.74 1.46 0.068 10
Bold indicates SNPs reaching nominally significance (p#0.05).
*Indicates significant SNP after Bonferroni correction for multiple testing.
doi:10.1371/journal.pone.0055709.t001
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[7], confirming validity of our pooling strategy. Log10 trans-
formation of baseline HbF had no effect on SNP associations; non-
transformed results are shown for comparison with induced values
(Table 1).
Baseline HbF. Given the fixed sample size and SNP allele
frequencies, the study had 90% power to detect differences in
average levels of baseline HbF% between 2.0 and 2.5 (Figure
S2A). Single marker SNP analysis revealed several significant
associations to baseline HbF (Table 1). One of two SNPs tested
within the HBB locus, rs7482144 [7], and the HBE SNP [19] were
significantly associated with baseline HbF after Bonferroni
correction. Six BCL11A SNPs were significantly associated with
baseline HbF, of which five withstood correction for multiple
comparisons, including the intronic variant, rs4671393 [6,7]. To
test for closer linkage disequilibrium with causal variants within
the BCL11A haplotype block than single SNPs [6], analysis
revealed several common haplotypes (frequency= 0.05), with
statistical association and effect size comparable to those seen
with single marker analysis (data not shown). Power was
insufficient to detect effects sizes of ,3, such as for markers in
the HBS1L-MYB intergenic region (Table 1).
Trend analysis using the SNP allele associated with higher
baseline HbF values (‘‘favorable allele’’) in one or both of the
BCL11A (rs4671393) and HBE (rs7130110) loci demonstrated
a statistically significant additive effect of each SNP and a two-fold
difference for both (ptrend,0.004) (Table 2). The HBB marker
(rs7482144) had effects identical to those of HBE (not shown). By
linear regression analysis of individual markers accounting for age
and sex, the percentage of baseline HbF variance attributable each
to the BCL11A or HBE SNP was 13%, and 10% for HBB (Table
S2A). In the multiple marker model, the BCL11A SNP combined
with either globin marker had an additive effect to 21–23%.
Contributions from HBE and HBB appeared to be redundant.
These two markers are in strong linkage disequilibrium within the
globin locus (r2 = 0.86, p,0.001), with different prevalence of the
minor allele: 18% for HBE and 12% for HBB.
Hydroxyurea-induced HbF. The study had $80% power
to detect SNPs with effect sizes larger than 2.5 with allele
frequencies of 0.25 or higher; estimated power decreased with
lower SNP allele frequencies (Figure S2B). Among all single
markers tested, only the HBE SNP [19] was significantly associated
with maximum HbF after correction for multiple testing, and
remained nominally associated even after adjusting for baseline
Figure 1. Baseline and hydroxyurea-induced maximum HbF for each subject (comparable to References 18, 19, 26).
doi:10.1371/journal.pone.0055709.g001
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HbF (p= 0.001) (Table 1). This same SNP was also unique in
being associated with the hydroxyurea-induced increment, delta
HbF (p = 0.004). Nominal associations were also found between
maximum HbF and four of the same six BCL11A SNPs associated
with baseline HbF (Table 1). However, no association of BCL11A
single marker with maximum HbF withstood adjustment for
baseline HbF (Table 1). Haplotype analysis of BCL11A indicated
nominal association with hydroxyurea-induced HbF, remaining at
borderline significant even after adjustment for baseline HbF (data
not shown).
By trend analysis, subjects with a favorable allele in at least one
of the BCL11A or HBE loci had higher average values, 20.8
(SD=7.5, N=23), compared to 15.5 (SD=5.6, N= 24) for those
without either allele (ptrend = 0.009) (Table 2). As with single SNP
analysis, statistical significance of this trend analysis did not
withstand adjustment for baseline fetal hemoglobin (p= 0.0.086).
As seen for baseline HbF, the HBB marker (rs7482144) had effects
identical to those of HBE (ptrend = 0.018, not shown). By linear
regression analysis of the three markers, alone or in combination,
only the HBE SNP independently and significantly added to the
phenotypic variance contributed by the baseline levels. In
combination, baseline level (33%) and the HBE (13%, p,0.001)
contributed an estimated 46% of the variance (Table S2B).
The GLP2R allele, not associated with baseline HbF, was
nominally associated with maximum HbF; the SAR1A SNP,
rs2310991, [21] was not.
Discussion
Children with sickle cell disease generally have higher baseline
HbF levels than adults and more pronounced HbF response to
hydroxyurea [5,6,7,8,9,11,13,16,18,19,20,26]. Findings from this
multi-site, observational analysis corroborate in children the
correlation between baseline and hydroxyurea-induced HbF levels
[18,19], and demonstrate that one third of the variance in induced
HbF is attributable to baseline levels. In contrast to the induced
HbF, the treatment-associated increment appears to be a less
relevant marker, as baseline and delta levels did not correlate and
those with high baseline more likely have highly inducible HbF%.
For baseline HbF, we confirm in children the associations
between single candidate markers in the BCL11A and HBB or
HBE loci [19]. Comparable marker contributions to baseline HbF
were reported for BCL11A and HBB in adult sickle cell disease
[6,7]. In our analysis, statistical effects on HbF from BCL11A and
either globin marker were additive, and were associated with two-
fold higher levels for patients with favorable alleles in both loci. An
apparent redundant influence exists between HBB and HBE
markers, suggesting a statistical effect stemming from tight linkage
and/or overlapping biologic effects.
For hydroxyurea-induced HbF, the HBE marker was the most
robustly associated with drug-induced HbF levels, an effect that
was independent of and additive to baseline levels. Despite
a sample size limiting statistical power for individual SNPs, trend
analysis with BCL11A and HBE or HBB markers suggests
substantially higher induced levels associated with one or both
favorable alleles. In combination with baseline levels, the HBE
accounted for almost half of the variance of induced levels. Taken
together, these data support a model of overlapping genetic
regulation of HbF in pediatric SCD for both steady states [17].
Roles of other SNP markers are less clear. Nominal association
with GLP2R for hydroxyurea-induced HbF, but not baseline, will
need confirmation and biologic rationale. No associations were
detected with SNPs in other candidate loci such as HBS1L-MYB,
presumably from insufficient power and its lesser impact on
baseline HbF in sickle cell disease [6]. Another hematologic
parameter, alpha-thalassemia status, is not independently associ-
ated with hydroxyurea-induced HbF in children [19]. Effects of
the drug’s pharmaco-kinetics on HbF response are unclear [19].
Limitations: Study limitations include sample size and observa-
tional assessment, where therapeutic approaches to hydroxyurea
and drug adherence may vary among sites despite inclusion
criteria. Nonetheless, hydroxyurea dose and distribution of drug-
induced HbF were comparable to those from prospective pediatric
hydroxyurea studies [18]. Moreover, a threshold hydroxyurea
dose of 20 mg/kg/day was employed to reduce HbF variability
from low drug dosing.
Clinically, HbF level is arguably the strongest predictor of
disease severity [2,3]. Baseline HbF in children remains the best
forecaster of hydroxyurea-induced HbF but accounts for only
a portion of drug response [19]. Despite a modest sample size,
clinically relevant differences in HbF [2,3] in our study population
appeared to be associated with specific alleles in three genetic loci.
These findings suggest that induced levels in pediatric disease
share some of the major regulatory loci associated with baseline
levels. Our HBE marker data also suggest that induced levels may
reflect effects that are additive to those of baseline. In summary,
our findings suggest that baseline and hydroxyurea-induced HbF
likely are influenced by these genetic loci, while distinct genetic,
pharmacologic, and clinical determinants also exist [18,19].
Genetic studies examining larger pediatric populations on
hydroxyurea and unusual responders are needed to assess the
specific sequence variants in these and other genetic loci
responsible for HbF response.
Supporting Information
Figure S1 Histograms for Baseline, Maximum and
Delta HbF%.
(JPG)
Figure S2 Power analyses based on minor allele fre-
quencies. S2A. Baseline HbF. S2B. Maximum HbF
(DOC)
Table 2. Incremental effect of allelotypes in BCL11A and HBE
on Baseline and Maximum HbF%.
Allelotype





rs4671393 rs7130110 HbF% (SD) HbF% (SD)
+ + 16 11.8 (5.2)
2 + 29 7.9 (5.3) 23# 20.8 (7.5)**
+ 2 18 8.8 (4.7)
2 2 45 6.4 (3.7)* 24 15.5 (5.6)
Baseline HbF%: Trend analysis across allelotypes: F(df,3) = 8.48, ptrend = 0.004.
Maximum HbF%: Trend analysis across 0 or $1 A alleles: F(df,2) = 7.43,
ptrend = 0.009.
The + denotes minor allele (A) associated with higher HbF%; the - denotes the
other allele (G),
with the BCL11A A or HBE allele in 1 or 2 copies.
*Reference allelotype.
**Not significant when adjusted for baseline HbF.
#Includes subjects with either or both minor A alleles.
doi:10.1371/journal.pone.0055709.t002
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Table S1 Clinical and Genetic Data by Study Site. S1A.
Clinical data by study site. S1B. Minor allele frequencies by study
site.
(DOC)
Table S2 HbF linear regression analysis to compare full
model consisting of age, sex, individual and multiple
SNPs. S2A. Baseline HbF%. S2B. Maximum HbF%
(DOC)
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